Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Feb;8(2):133-9.
doi: 10.1111/j.1524-6175.2006.05110.x.

Aldosterone--a hormone of cardiovascular adaptation and maladaptation

Affiliations
Review

Aldosterone--a hormone of cardiovascular adaptation and maladaptation

Theodore L Goodfriend. J Clin Hypertens (Greenwich). 2006 Feb.

Abstract

Aldosterone stimulates reabsorption of sodium, sustaining blood volume and pressure in the face of salt deprivation or extracellular fluid depletion. The steroid also stimulates excretion of potassium, protecting extracellular fluid from excessive levels of that ion. These two actions are relatively rapid and clearly adaptive when appropriately initiated and terminated, but maladaptive when prolonged or excessive, causing hypertension and electrolyte imbalance. Aldosterone and other mineralocorticoids exert slower, direct effects on cells in the heart, kidneys, and vessels, leading to hypertrophy, fibrosis, and dysfunction contributing to degenerative cardiovascular diseases. The maladaptive actions of aldosterone are exacerbated by sodium chloride, angiotensin, endothelin, and certain growth factors. Damage can be minimized by antagonists of aldosterone receptors, inhibitors of the renin system, depletion of salt, and repletion of potassium and magnesium. Specific inhibitors of fibrosis and hypertrophy, and more effective inhibitors of the renin system should be useful in the future.

PubMed Disclaimer

References

    1. Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor‐1 production. J Clin Endocrinol Metab. 2000;85: 336–344. - PubMed
    1. Funder JW. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J. 2002;144(5 suppl):S8–S11. - PubMed
    1. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43: 518–524. - PubMed
    1. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonists spironolactone prevents post‐infarct left ventricular remodeling associated with suppression of a marker myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107: 2559–2565. - PubMed
    1. Losel R, Schultz A, Wehling M. A quick glance at rapid aldosterone action. Mol Cell Endocrinol. 2004;217: 137–141. - PubMed

MeSH terms